1
|
Bahlis NJ, Siegel DS, Schiller GJ, Samaras C, Sebag M, Berdeja J, Ganguly S, Matous J, Song K, Seet CS, Acosta-Rivera M, Bar M, Quick D, Anz B, Fonseca G, Chung W, Lee K, Mouro J, Agarwal A, Reece D. Pomalidomide, dexamethasone, and daratumumab immediately after lenalidomide-based treatment in patients with multiple myeloma: updated efficacy, safety, and health-related quality of life results from the phase 2 MM-014 trial. Leuk Lymphoma 2022; 63:1407-1417. [PMID: 35133221 DOI: 10.1080/10428194.2022.2030477] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
Patients with relapsed/refractory multiple myeloma (RRMM) need proven subsequent therapies after early-line lenalidomide treatment failure. The phase 2 MM-014 trial (NCT01946477) investigated pomalidomide, dexamethasone, and daratumumab after 1 to 2 prior treatment lines (62.5%, 1 prior line) in patients with RRMM and prior lenalidomide (75.0%, lenalidomide refractory). With a median follow-up of 28.4 months, overall response rate was 77.7% (52.7% achieved very good partial response or better) and median progression-free survival was 30.8 months. For patients with lenalidomide-refractory disease, these outcomes were 76.2%, 47.6%, and 23.7 months, respectively. No new safety signals were observed; 64.3% experienced grade 3/4 neutropenia. Health-related quality of life was preserved or trended toward improvement through 12 treatment cycles. Pomalidomide, dexamethasone, and daratumumab given immediately after early-line lenalidomide-based treatment continues to demonstrate safety and efficacy, supporting pomalidomide-dexamethasone as a foundation of combination therapy in RRMM and providing evidence that the immunomodulatory agent class delivers benefit after lenalidomide treatment failure.
Collapse
Affiliation(s)
| | - David S Siegel
- John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA
| | - Gary J Schiller
- David Geffen School of Medicine, University of California, Los Angeles, CA, USA
| | | | - Michael Sebag
- McGill University Health Centre, Montreal, QC, Canada
| | | | | | | | - Kevin Song
- Vancouver General Hospital, Vancouver, BC, Canada
| | - Christopher S Seet
- David Geffen School of Medicine, University of California, Los Angeles, CA, USA
| | | | | | - Donald Quick
- Joe Arrington Cancer Research and Treatment Center, Lubbock, TX, USA
| | | | | | | | - Kim Lee
- Bristol Myers Squibb, Princeton, NJ, USA
| | - Jorge Mouro
- Celgene International Sàrl, A Bristol-Myers Squibb Company, Boudry, Switzerland
| | | | - Donna Reece
- Princess Margaret Cancer Centre, Toronto, ON, Canada
| |
Collapse
|
2
|
Bar M, Fish E, Mendlovic S. Mental-health care under threat: a pragmatic approach for ethical decision-making for practitioners in COVID-19. Counselling Psychology Quarterly 2020. [DOI: 10.1080/09515070.2020.1777939] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Affiliation(s)
- M. Bar
- Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
- Psychiatric Division, Sheba Medical Center, Ramat-Gan, Israel
| | - E. Fish
- Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - S. Mendlovic
- Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
- Director, the Shalvata Mental Health Center, Shalvata Mental Health Center, Hod Hasharon, Israel
- Psychotherapy Program, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel
| |
Collapse
|
3
|
Siegel DS, Schiller GJ, Samaras C, Sebag M, Berdeja J, Ganguly S, Matous J, Song K, Seet CS, Talamo G, Acosta-Rivera M, Bar M, Quick D, Anz B, Fonseca G, Reece D, Pierceall WE, Chung W, Zafar F, Agarwal A, Bahlis NJ. Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment. Leukemia 2020; 34:3286-3297. [PMID: 32376855 PMCID: PMC7685974 DOI: 10.1038/s41375-020-0813-1] [Citation(s) in RCA: 51] [Impact Index Per Article: 12.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2020] [Revised: 03/06/2020] [Accepted: 03/20/2020] [Indexed: 12/16/2022]
Abstract
Patients with multiple myeloma who have relapsed after or become refractory to lenalidomide in early treatment lines represent a clinically important population in need of effective therapies. The safety and efficacy of pomalidomide, low-dose dexamethasone, and daratumumab was evaluated in lenalidomide-pretreated patients with relapsed or refractory multiple myeloma (RRMM) after one to two prior treatment lines in the phase 2 MM-014 study. Patients received pomalidomide 4 mg daily from days 1-21 and dexamethasone 40 mg weekly (28-day cycles). Daratumumab 16 mg/kg was administered per label. Primary endpoint was overall response rate (ORR); secondary endpoints included progression-free survival (PFS) and safety. Per protocol, all patients (N = 112) had received lenalidomide in their most recent prior regimen (75.0% lenalidomide refractory). ORR was 77.7% (76.2% in lenalidomide-refractory patients); median follow-up was 17.2 months. Median PFS was not reached (1-year PFS rate 75.1%). The most common hematologic grade 3/4 treatment-emergent adverse event was neutropenia (62.5%). Grade 3/4 infections were reported in 31.3% of patients, including 13.4% with grade 3/4 pneumonia. These results demonstrate the safety and efficacy of pomalidomide-based therapy as early as second line in patients with RRMM, even immediately after lenalidomide failure, indicating that switching from the immunomodulatory agent class is not necessary.
Collapse
Affiliation(s)
- David S Siegel
- John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA.
| | - Gary J Schiller
- David Geffen School of Medicine at University of California, Los Angeles, CA, USA
| | | | - Michael Sebag
- McGill University Health Centre, Montreal, QC, Canada
| | | | | | | | - Kevin Song
- Vancouver General Hospital, Vancouver, BC, Canada
| | - Christopher S Seet
- David Geffen School of Medicine at University of California, Los Angeles, CA, USA
| | | | | | | | - Donald Quick
- Joe Arrington Cancer Research and Treatment Center, Lubbock, TX, USA
| | | | | | - Donna Reece
- Princess Margaret Cancer Centre, Toronto, ON, Canada
| | | | | | | | | | - Nizar J Bahlis
- Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, AB, Canada
| |
Collapse
|
4
|
Bužgová R, Kozáková R, Bar M, Škutová M, Ressner P, Bártová P. Differences in attitudes to ethic aspects of end of life care among patients with progressive neurological diseases and their family members. J Neurol Sci 2019. [DOI: 10.1016/j.jns.2019.10.418] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
5
|
Reece DE, Bahlis NJ, Samaras CJ, Sebag M, Berdeja JG, Ganguly S, Matous J, Song KW, Seet C, Talamo G, Acosta-Rivera M, Bar M, Quick D, Anz BM, Fonseca GA, Agarwal A, Chung W, Zafar F, Siegel DSD. A health-related quality-of-life (HRQoL) analysis of pomalidomide + low-dose dexamethasone + daratumumab in relapsed refractory multiple myeloma (RRMM) after lenalidomide treatment. J Clin Oncol 2019. [DOI: 10.1200/jco.2019.37.15_suppl.8025] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
8025 Background: Treatment (Tx) of RRMM is complex and requires evaluation of disease and patient (pt) factors to maximize efficacy and minimize toxicity. HRQoL has become an important aspect of MM Tx, as survival has improved with therapeutic advances. Results of the ongoing phase 2 MM-014 trial (NCT01946477) have demonstrated that pomalidomide (POM) + low-dose dexamethasone (LoDEX) + daratumumab (DARA) is safe and effective in RRMM pts after first- or second-line lenalidomide (LEN)-based Tx failure. Here we report the impact of this regimen on HRQoL. Methods: RRMM pts with 1 to 2 prior Tx lines, LEN-based Tx as their most recent regimen, and progressive disease during or after their last Tx line received POM + LoDEX + DARA in 28-day cycles (MM-014 cohort B). HRQoL, an exploratory endpoint for cohort B, was assessed via EuroQol’s EQ-5D. Results: As of October 15, 2018, 108 pts were evaluable for HRQoL. Baseline characteristics were similar to those of the ITT population (N = 112). EQ-5D completion rates for each cycle (1-6) were ≥ 88%. Mean change from baseline in the EQ-5D index and VAS health score was stable through 6 Tx cycles. At cycle 6, 28.8% and 39.0% of pts achieved minimum clinically important improvement in the EQ-5D index (≥ 0.1) and VAS health score (≥ 6), respectively. EQ-5D index values were stable, with a trend toward improvement in usual activities, pain/discomfort, and anxiety/depression (Table). Conclusions: In RRMM pts with early-line LEN Tx failure, HRQoL was maintained or trended toward improvement with POM + LoDEX + DARA, despite the combination of 3 drugs with distinct toxicities. These findings further support the earlier use of POM-based Tx in RRMM immediately after LEN failure. Clinical trial information: NCT01946477. [Table: see text]
Collapse
Affiliation(s)
| | | | | | - Michael Sebag
- McGill University Health Centre, Montréal, QC, Canada
| | | | | | | | | | | | | | | | | | - Donald Quick
- Joe Arrington Cancer Research and Treatment Center, Lubbock, TX
| | | | | | | | | | | | | |
Collapse
|
6
|
Migaľová P, Formánek M, Krulová P, Bar M, Jančatová D, Zákopčanová - Srovnalová H, Tomášková H, Komínek P. Repetitive transcranial magnetic stimulation for the treatment of chronic subjective non-pulsatile primary tinnitus - case report. Brain Stimul 2019. [DOI: 10.1016/j.brs.2018.12.861] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
7
|
Siegel DSD, Schiller GJ, Samaras CJ, Sebag M, Berdeja JG, Ganguly S, Matous J, Song KW, Seet C, Talamo G, Srinivas S, Acosta-Rivera M, Bar M, Quick D, Anz BM, Fonseca G, Reece DE, Zafar F, Chung W, Bahlis NJ. Pomalidomide (POM) + low-dose dexamethasone (LoDEX) + daratumumab (DARA) in relapsed and/or refractory multiple myeloma (RRMM) after lenalidomide (LEN)-based treatment (Tx) failure. J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.15_suppl.8027] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | | | - Michael Sebag
- McGill University Health Centre, Montréal, QC, Canada
| | | | | | | | | | | | | | - Shanthi Srinivas
- Veterans Administration New Jersey Health Care System, East Orange, NJ
| | | | | | - Donald Quick
- Joe Arrington Cancer Research and Treatment Center, Lubbock, TX
| | | | | | | | | | | | | |
Collapse
|
8
|
Pizarro L, Leibman-Markus M, Schuster S, Bar M, Avni A. SlPRA1A/RAB attenuate EIX immune responses via degradation of LeEIX2 pattern recognition receptor. Plant Signal Behav 2018; 13:e1467689. [PMID: 29944445 PMCID: PMC6103275 DOI: 10.1080/15592324.2018.1467689] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/08/2023]
Abstract
Pattern recognition receptors (PRR) are plasma membrane (PM) proteins that recognize microbe-associated molecular patterns (MAMPs), triggering an immune response. PRR are classified as receptor like kinases (RLKs) or receptor like proteins (RLPs). The PM localization of PRRs, which is crucial for their availability to sense MAMPs, depends on their appropriate trafficking through the endomembrane system. Recently, we have identified SlPRA1A, a prenylated RAB acceptor type-1 (PRA1) from S. lycopersicum, as a regulator of RLP-PRR localization and protein levels. SlPRA1A overexpression strongly decreases RLP-PRR protein levels, particularly those of LeEIX2, redirecting it to the vacuole for degradation. Interestingly, SlPRA1A does not affect RLK-PRRs, indicating its activity to be specific to RLP-PRR systems. As PRA1 proteins stabilize RABs on membranes, promoting RABs activity, we aimed to identify a RAB target of SlPRA1A. Screening of a set of A. thaliana RABs revealed that AtRABA1e is able to mimic SlPRA1A activity. Through live cell imaging, we observed that SlPRA1A enhances AtRABA1e localization on SlPRA1A positive punctuated structures. These results indicate that AtRABA1e is a putative target of SlPRA1, and a co-regulator of LeEIX2 trafficking and degradation.
Collapse
Affiliation(s)
- L. Pizarro
- School of Plant Sciences and Food Security, Tel Aviv University, Tel Aviv, Israel
| | - M. Leibman-Markus
- School of Plant Sciences and Food Security, Tel Aviv University, Tel Aviv, Israel
| | - S. Schuster
- School of Plant Sciences and Food Security, Tel Aviv University, Tel Aviv, Israel
| | - M. Bar
- Department of Plant Pathology and Weed Research, ARO, The Volcani Center, Rishon LeZion, Israel
| | - A. Avni
- School of Plant Sciences and Food Security, Tel Aviv University, Tel Aviv, Israel
- CONTACT A. Avni School of Plant Sciences and Food Security, Tel Aviv University, Tel Aviv, Israel
| |
Collapse
|
9
|
Slonkova J, Bar M, Nilius P, Berankova-Fiedorova D, Salounova D, Sonka K. Spontaneous improvement in both obstructive sleep apnea and cognitive impairment after stroke. Sleep Med 2017. [DOI: 10.1016/j.sleep.2017.11.910] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
10
|
Mikulik R, Bar M, Grecu A, Herzig R, Neumann J, Sanak D, Skoda O, Skoloudik D, Svobodova V, Tomek A, Vaclavik D. The registry of stroke care quality (RES-Q): The first nation-wide data on stroke care quality. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.302] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
11
|
Herzig R, Waishaupt J, Belaskova S, Vitkova E, Blejcharova K, Geier P, Tomek A, Bar M, Vaclavik D, Mikulik R, Valis M. Risk of intracranial hemorrhage and clinical outcome after intravenous thrombolysis in posterior circulation stroke: Results from the sits-east registry. J Neurol Sci 2017. [DOI: 10.1016/j.jns.2017.08.3653] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
12
|
Slonkova J, Bar M, Nilius P, Berankova D, Salounova D, Sonka K. Spontaneous improvement in both obstructive sleep apnea and cognitive impairment after stroke. Sleep Med 2017; 32:137-142. [PMID: 28366325 DOI: 10.1016/j.sleep.2016.11.024] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/25/2016] [Revised: 10/31/2016] [Accepted: 11/10/2016] [Indexed: 11/27/2022]
Abstract
BACKGROUND Knowledge available about the relationship between obstructive sleep apnea (OSA) and cognitive impairment after stroke is limited. The evolution of OSA and cognitive performance after stroke is not sufficiently described. METHODS We prospectively enrolled and examined acute stroke patients without previously diagnosed OSA. The following information was collected: (1) demographics, (2) sleep cardio-respiratory polygraphy (PG) at 72 h, day seven, month three, and month 12 after stroke, (3) post-stroke functional disability tests at entry and at months three and 12, and (4) cognition (attention and orientation, memory, verbal fluency, language, and visual-spatial abilities) using the revised Addenbrooke's Cognitive Examination (ACE-R) at months three and 12. RESULTS Of 68 patients completing the study, OSA was diagnosed in 42 (61.8%) patients. The mean apnea/hypopnea index (AHI) at study entry of 21.0 ± 13.7 spontaneously declined to 11.6 ± 11.2 at month 12 in the OSA group (p < 0.0005). The total ACE-R score was significantly reduced at months three (p = 0.005) and 12 (p = 0.004) in the OSA group. Poorer performance on the subtests of memory at months 3 (p = 0.039) and 12 (p = 0.040) and verbal fluency at months 3 (p < 0.005) and 12 (p < 0.005) were observed in the OSA group compared to non-OSA group. Visual-spatial abilities in both the OSA (p = 0.001) and non-OSA (p = 0.046) groups and the total ACE-R score in the OSA (p = 0.005) and non-OSA (p = 0.002) groups improved. CONCLUSIONS A high prevalence of OSA and cognitive decline were present in patients after an acute stroke. Spontaneous improvements in both OSA and cognitive impairment were observed.
Collapse
Affiliation(s)
- J Slonkova
- Department of Neurology, Faculty Hospital Ostrava, 17. Listopadu 1790, 708 52, Ostrava, Czech Republic.
| | - M Bar
- Department of Neurology, Faculty Hospital Ostrava, 17. Listopadu 1790, 708 52, Ostrava, Czech Republic; Faculty of Medicine, University of Ostrava, Syllabova 19, 703 00, Ostrava-jih, Czech Republic.
| | - P Nilius
- Philosophical Faculty, Palacky University Olomouc, Krizkovskeho 512/10, 779 00, Olomouc, Czech Republic.
| | - D Berankova
- Department of Neurology, Faculty Hospital Ostrava, 17. Listopadu 1790, 708 52, Ostrava, Czech Republic.
| | - D Salounova
- Faculty of Economics, VSB - Technical University of Ostrava, Sokolska 33, Ostrava, 701 21, Czech Republic.
| | - K Sonka
- Department of Neurology, First Faculty of Medicine, Charles University in Prague, Prague, 128 21, Czech Republic.
| |
Collapse
|
13
|
Espina C, Jenkins I, Taylor L, Farah R, Cho E, Epworth J, Coleman K, Pinelli J, Mentzer S, Jarrett L, Gooley T, O'Donnell P, Hirsch IB, Bar M. Blood glucose control using a computer-guided glucose management system in allogeneic hematopoietic cell transplant recipients. Bone Marrow Transplant 2016; 51:973-9. [PMID: 27042836 DOI: 10.1038/bmt.2016.78] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2015] [Revised: 02/13/2016] [Accepted: 02/19/2016] [Indexed: 12/18/2022]
Abstract
Allogeneic hematopoietic cell transplantation (HCT) is a potentially curative treatment for patients with hematological malignancies. However, is associated with substantial rates of morbidity and mortality. We and others have shown that malglycemia is associated with adverse transplant outcome. Therefore, improving glycemic control may improve transplant outcome. In this prospective study we evaluated the feasibility of using Glucommander (a Computer-Guided Glucose Management System; CGGM) in order to achieve improved glucose control in hospitalized HCT patients. Nineteen adult patients contributed 21 separate instances on CGGM. Patients were on CGGM for a median of 43 h. Median initial blood glucose (BG) on CGGM was 244 mg/dL, and patients on 20 study instances reached the study BG target of 100-140 mg/dL after a median of 6 h. After BG reached the target range, the median average BG level per patient was 124 mg/dL. Six patients had a total of 10 events of BG <70 mg/dL (0.9% of BG measurements), and no patients experienced BG level <40 mg/dL. The total estimated duration of BG <70 mg/dL was 3 h (0.2% of the total CGGM time). In conclusion, our study demonstrates that stringent BG control in HCT patients using CGGM is feasible.
Collapse
Affiliation(s)
- C Espina
- Internal Medicine, University of Washington, Seattle, WA, USA
| | - I Jenkins
- Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | - L Taylor
- Internal Medicine, University of Washington, Seattle, WA, USA
- Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | - R Farah
- UPMC Cancer Center, Pittsburgh, PA, USA
| | - E Cho
- Internal Medicine, University of Washington, Seattle, WA, USA
- Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | - J Epworth
- Internal Medicine, University of Washington, Seattle, WA, USA
| | - K Coleman
- Internal Medicine, University of Washington, Seattle, WA, USA
- Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | - J Pinelli
- Internal Medicine, University of Washington, Seattle, WA, USA
- Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | - S Mentzer
- Internal Medicine, University of Washington, Seattle, WA, USA
- Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | - L Jarrett
- Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | - T Gooley
- Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | - P O'Donnell
- Internal Medicine, University of Washington, Seattle, WA, USA
- Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
- Massachusetts General Hospital Cancer Center, Boston, MA, USA
| | - I B Hirsch
- Internal Medicine, University of Washington, Seattle, WA, USA
| | - M Bar
- Internal Medicine, University of Washington, Seattle, WA, USA
- Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| |
Collapse
|
14
|
Vadas L, Altman D, Bar M, Seltzer O, Ahron M, Azulay S, Mazzawi N, Reshef A, Haimov I, Bloch B. Sleep in Schizophrenic Patients: Discrepancy Between Self-reported Versus Recorded Sleep. Eur Psychiatry 2015. [DOI: 10.1016/s0924-9338(15)30731-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
15
|
Vakhrusheva J, Zemon V, Bar M, Weiskopf NG, Tremeau F, Petkova E, Su Z, Abeles I, Butler PD. Forming first impressions of others in schizophrenia: impairments in fast processing and in use of spatial frequency information. Schizophr Res 2014; 160:142-9. [PMID: 25458862 PMCID: PMC4258115 DOI: 10.1016/j.schres.2014.10.012] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/18/2014] [Revised: 09/14/2014] [Accepted: 10/09/2014] [Indexed: 11/30/2022]
Abstract
Individuals form first impressions of others all the time, which affects their social functioning. Typical adults form threat impressions in faces with neutral expressions quickly, requiring less than 40 ms. These impressions appear to be mediated by low spatial frequency (LSF) content in the images. Little is known, however, about mechanisms of first impression formation in schizophrenia. The current study investigated how quickly individuals with schizophrenia can form consistent impressions of threat compared with controls and explored the mechanisms involved. Patients and controls were presented intact, LSF- or high spatial frequency (HSF)-filtered faces with durations that varied from 39 to 1703 ms and were asked to rate how threatening each face was on a scale from 1 to 5. In order to assess the speed of impression formation for intact faces, correlations were calculated for ratings made at each duration compared to a reference duration of 1703 ms for each group. Controls demonstrated a significant relation for intact faces presented for 39 ms, whereas patients required 390 ms to demonstrate a significant relation with the reference duration. For controls, LSFs primarily contributed to the formation of consistent threat impressions at 39 ms, whereas patients showed a trend for utilizing both LSF and HSF information to form consistent threat impressions at 390 ms. Results indicate that individuals with schizophrenia require a greater integration time to form a stable "first impression" of threat, which may be related to the need to utilize compensatory mechanisms such as HSF, as well as LSF, information.
Collapse
Affiliation(s)
- J Vakhrusheva
- Ferkauf Graduate School of Psychology, Yeshiva University,
Bronx, NY
| | - V Zemon
- Ferkauf Graduate School of Psychology, Yeshiva University,
Bronx, NY, Nathan S. Kline Institute for Psychiatric Research, Orangeburg,
NY
| | - M Bar
- Gonda Multidisciplinary Brain Research Center, Bar-Ilan University, Ramat Gan, Israel; Martinos Center at Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, United States.
| | - NG Weiskopf
- Nathan S. Kline Institute for Psychiatric Research, Orangeburg,
NY, Department of Biomedical Informatics, Columbia University, New
York, NY
| | - F Tremeau
- Nathan S. Kline Institute for Psychiatric Research, Orangeburg,
NY
| | - E Petkova
- Nathan S. Kline Institute for Psychiatric Research, Orangeburg,
NY, Department of Child and Adolescent Psychiatry, New York
University Langone Medical Center, New York, NY 10016
| | - Z Su
- Department of Child and Adolescent Psychiatry, New York
University Langone Medical Center, New York, NY 10016
| | - I Abeles
- Nathan S. Kline Institute for Psychiatric Research, Orangeburg,
NY, Department of Psychiatry, New York University School of
Medicine, New York, NY, Department of Psychology, City University of New York, New York,
NY
| | - PD Butler
- Nathan S. Kline Institute for Psychiatric Research, Orangeburg,
NY, Department of Psychiatry, New York University School of
Medicine, New York, NY, Department of Psychology, City University of New York, New York,
NY
| |
Collapse
|
16
|
Cheung OS, Bar M. The role of the orbitofrontal cortex in visual prediction. J Vis 2013. [DOI: 10.1167/13.9.785] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
17
|
Chapuis A, Ragnarsson GB, Nguyen HN, Chaney CN, Pufnock JS, Schmitt TM, Duerkopp N, Roberts IM, Pogosov GL, Ho WY, Ochsenreither S, Wölfl M, Bar M, Radich JP, Yee C, Greenberg PD. Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients. Sci Transl Med 2013; 5:174ra27. [PMID: 23447018 PMCID: PMC3678970 DOI: 10.1126/scitranslmed.3004916] [Citation(s) in RCA: 256] [Impact Index Per Article: 23.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
Relapse remains a leading cause of death after allogeneic hematopoietic cell transplantation (HCT) for patients with high-risk leukemias. The potentially beneficial donor T cell-mediated graft-versus-leukemia (GVL) effect is often mitigated by concurrent graft-versus-host disease (GVHD). Providing T cells that can selectively target Wilms tumor antigen 1 (WT1), a transcription factor overexpressed in leukemias that contributes to the malignant phenotype, represents an opportunity to promote antileukemic activity without inducing GVHD. HLA-A*0201-restricted WT1-specific donor-derived CD8 cytotoxic T cell (CTL) clones were administered after HCT to 11 relapsed or high-risk leukemia patients without evidence of on-target toxicity. The last four treated patients received CTL clones generated with exposure to interleukin-21 (IL-21) to prolong in vivo CTL survival, because IL-21 can limit terminal differentiation of antigen-specific T cells generated in vitro. Transferred cells exhibited direct evidence of antileukemic activity in two patients: a transient response in one patient with advanced progressive disease and the induction of a prolonged remission in a patient with minimal residual disease (MRD). Additionally, three treated patients at high risk for relapse after HCT survive without leukemia relapse, GVHD, or additional antileukemic treatment. CTLs generated in the presence of IL-21, which were transferred in these latter three patients and the patient with MRD, all remained detectable long-term and maintained or acquired in vivo phenotypic and functional characteristics associated with long-lived memory CD8 T cells. This study supports expanding efforts to immunologically target WT1 and provides insights into the requirements necessary to establish potent persistent T cell responses.
Collapse
Affiliation(s)
- A.G. Chapuis
- Program in Immunology, Fred Hutchinson Cancer Research Center (FHCRC), Seattle, WA, USA
| | - G. B. Ragnarsson
- Program in Immunology, Fred Hutchinson Cancer Research Center (FHCRC), Seattle, WA, USA
| | - H. N. Nguyen
- Program in Immunology, Fred Hutchinson Cancer Research Center (FHCRC), Seattle, WA, USA
| | - C. N. Chaney
- Program in Immunology, Fred Hutchinson Cancer Research Center (FHCRC), Seattle, WA, USA
| | - J. S. Pufnock
- Program in Immunology, Fred Hutchinson Cancer Research Center (FHCRC), Seattle, WA, USA
| | - T. M. Schmitt
- Program in Immunology, Fred Hutchinson Cancer Research Center (FHCRC), Seattle, WA, USA
| | - N. Duerkopp
- Program in Immunology, Fred Hutchinson Cancer Research Center (FHCRC), Seattle, WA, USA
| | - I. M. Roberts
- Program in Immunology, Fred Hutchinson Cancer Research Center (FHCRC), Seattle, WA, USA
| | | | - W. Y. Ho
- Program in Immunology, Fred Hutchinson Cancer Research Center (FHCRC), Seattle, WA, USA
| | - S. Ochsenreither
- Program in Immunology, Fred Hutchinson Cancer Research Center (FHCRC), Seattle, WA, USA
| | - M. Wölfl
- Program in Immunology, Fred Hutchinson Cancer Research Center (FHCRC), Seattle, WA, USA
| | - M. Bar
- Clinical Research Division, FHCRC, Seattle, WA, USA
| | - J. P. Radich
- Clinical Research Division, FHCRC, Seattle, WA, USA
| | - C Yee
- Program in Immunology, Fred Hutchinson Cancer Research Center (FHCRC), Seattle, WA, USA
| | - P. D. Greenberg
- Program in Immunology, Fred Hutchinson Cancer Research Center (FHCRC), Seattle, WA, USA
- Department of Immunology, University of Washington, Seattle, WA, USA
| |
Collapse
|
18
|
Shreders A, Bar M. A case of seronegative catastrophic antiphospholipid antibody syndrome. Conn Med 2013; 77:81-83. [PMID: 23513635] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
Catastrophic antiphospholipid antibody syndrome (CAPS) is a rare syndrome associated with multiorgan failure that carries a high mortality rate. It has been defined previously by the presence of autoantibodies in a patient with acute multiorgan failure as a result of small vessel occlusion by multiple thrombi. We report a patient who meets all criteria of CAPS except for persistent seronegativity.
Collapse
Affiliation(s)
- Amanda Shreders
- Stamford Hospital/Columbia University, College of Physicians and Surgeons, 30 Shelburne Road, Stamford, CT 06904, USA
| | | |
Collapse
|
19
|
Rektor I, Krauss GL, Bar M, Biton V, Klapper JA, Vaiciene-Magistris N, Kuba R, Squillacote D, Gee M, Kumar D. Perampanel Study 207: long-term open-label evaluation in patients with epilepsy. Acta Neurol Scand 2012; 126:263-9. [PMID: 22913800 DOI: 10.1111/ane.12001] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/17/2012] [Indexed: 11/29/2022]
Abstract
OBJECTIVES Evaluate interim long-term tolerability, safety and efficacy of adjunctive perampanel, a novel α-amino-3-hydroxy-5-methyl-5-isoxazolepropionic acid (AMPA)-receptor antagonist, in patients with refractory partial-onset seizures. MATERIALS AND METHODS Study 207, an open-label extension (OLE) study (ClinicalTrials.gov identifier: NCT00368472), enrolled patients (18-70 years) who completed one of two randomized, placebo-controlled, dose-escalation Phase II studies. The OLE Treatment Phase comprised a 12-week Titration Period (2 mg increments of perampanel every 2 weeks to 12 mg/day, maximum) and a Maintenance Period, during which patients continued treatment up to a planned maximum of 424 weeks (~8 years). Interim analysis data cut-off date was 1 December, 2010. RESULTS Of 180 patients completing the Phase II studies, 138 enrolled in study 207. At the time of interim analyses (approximately 4 years after study start), over a third (n = 53, 38.4%) remained on perampanel; 41.3% (n = 57) of patients had >3 years of exposure; and 13.0% (n = 18) had at least 4 years' exposure. Mean ± standard deviation (SD) duration of exposure was 116 ± 75 weeks and mean ± SD dose during the OLE Maintenance Period was 7.3 ± 3.3 mg. No new safety signals emerged with long-term treatment. Consistent with previous studies, the most common treatment-emergent adverse events were as follows: dizziness, headache and somnolence. Overall median (range) per cent change from baseline in seizure frequency per 28 days during open-label treatment was -31.5% (-99.2 to 512.2). CONCLUSIONS Long-term - up to 4 years - adjunctive perampanel had a favourable tolerability profile in patients with refractory partial-onset seizures. Improvements in seizure control were maintained with long-term treatment.
Collapse
Affiliation(s)
| | | | - M. Bar
- Faculty of Medicine; University of Ostrava and Faculty Hospital Ostrava; Ostrava; Czech Republic
| | - V. Biton
- Arkansas Epilepsy Program; Little Rock; AR; USA
| | | | | | | | - D. Squillacote
- Eisai Neuroscience Product Creation Unit; Woodcliff Lake; NJ; USA
| | | | - D. Kumar
- Eisai Neuroscience Product Creation Unit; Woodcliff Lake; NJ; USA
| |
Collapse
|
20
|
Kveraga K, Boshyan J, Adams R, Hamalainen M, Hadjikhani N, Bar M, Feldman Barrett L. Spatiotemporal dynamics and neural synchrony during perception of threatening vs. merely negative visual scenes. J Vis 2012. [DOI: 10.1167/12.9.594] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
21
|
|
22
|
Bar M, Mikulik R, Jonszta T, Krajina A, Roubec M, Skoloudik D, Prochazka V. Diagnosis of recanalization of the intracranial artery has poor inter-rater reliability. AJNR Am J Neuroradiol 2012; 33:972-4. [PMID: 22241381 DOI: 10.3174/ajnr.a2896] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
BACKGROUND AND PURPOSE Recanalization is the important outcome measure for acute stroke therapy. Several methods of recanalization assessment are used in clinical practice, but few studies have addressed their reliability. We, therefore, sought to assess interobserver reliability of the diagnosis of intracranial artery recanalization following intervention by using TIMI criteria. MATERIALS AND METHODS The digital angiography scans of all patients with acute ischemic stroke during 2009 undergoing DSA and endovascular procedures at Ostrava University Hospital were assessed in the study. Images were retrospectively evaluated for intracranial artery recanalization on the TIMI scale by 2 experienced neuroradiologists who were blinded to clinical findings and to each other. RESULTS The angiography scans of 43 patients (16 females; age, 70.5 ± 14 years; median baseline NIHSS score, 15 [IQR, 11-18]) were retrospectively evaluated in our study. At 3 months, 27% of patients had mRS scores ≤ 2 and mortality was 18%. Two radiologists diagnosed TIMI grades as follows: TIMI 0, 16%, and 16%; TIMI 1, 21%, and 8%; TIMI 2a, 32% and 29%; TIMI 2b, 13% and 16%; TIMI 3, 18, and 31%. Interobserver agreement for recanalization was weighted κ = 0.4 (95% CI, 0.2-0.6). CONCLUSIONS The diagnosis of recanalization after interventional procedures was found to have poor interobserver agreement between 2 experienced neuroradiologists. TIMI criteria, therefore, do not permit reliable comparison of the efficacy of recanalization therapy among different studies.
Collapse
Affiliation(s)
- M Bar
- Department of Neurology and Radiology, Faculty Hospital and Faculty of Medicine, University Ostrava, Czech Republic.
| | | | | | | | | | | | | |
Collapse
|
23
|
Krauss GL, Bar M, Biton V, Klapper JA, Rektor I, Vaiciene-Magistris N, Squillacote D, Kumar D. Tolerability and safety of perampanel: two randomized dose-escalation studies. Acta Neurol Scand 2012; 125:8-15. [PMID: 21883097 DOI: 10.1111/j.1600-0404.2011.01588.x] [Citation(s) in RCA: 85] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
OBJECTIVES To evaluate, for the first time in patients with epilepsy, the tolerability and safety of escalating doses of oral perampanel, a novel, selective, non-competitive AMPA antagonist, as adjunctive therapy for refractory partial-onset seizures. MATERIALS AND METHODS Two consecutive, randomized, double-blind, dose-escalation studies recruited adults (18-70 years) with uncontrolled partial-onset seizures receiving one to three concomitant antiepileptic drugs. In study 206, patients were treated for 12 weeks (8-week dose-titration, 4-week dose-maintenance) with placebo or perampanel (up to 4 mg/day, dosed once- or twice-daily). In study 208, patients received placebo or perampanel once-daily (up to 12 mg) for 16 weeks (12-week titration, 4-week maintenance). RESULTS Overall, 153 patients were randomized into study 206 (perampanel twice-daily, n = 51; perampanel once-daily, n = 51; placebo, n = 51). Study 208 included 48 patients (perampanel once-daily, n = 38; placebo, n = 10). The highest dose in study 206 - 4 mg/day - was well tolerated, with similar proportions of patients tolerating once-daily (82.4%) and twice-daily (82.4%) perampanel and placebo (82.4%) treatments. In study 208 most patients tolerated doses of ≥ 6 mg perampanel once-daily in a Kaplan-Meier analysis. In both studies, the most common adverse events were CNS-related; most were of mild/moderate severity. CONCLUSIONS Perampanel was well tolerated across doses of 4-12 mg/day. The studies showed preliminary evidence of efficacy and identified doses to be evaluated in larger clinical studies.
Collapse
Affiliation(s)
- G L Krauss
- Johns Hopkins Hospital, Baltimore, MD 21287, USA.
| | | | | | | | | | | | | | | |
Collapse
|
24
|
Richardson PG, Wolf J, Jakubowiak A, Zonder J, Lonial S, Irwin D, Densmore J, Krishnan A, Raje N, Bar M, Martin T, Schlossman R, Ghobrial IM, Munshi N, Laubach J, Allerton J, Hideshima T, Colson K, Poradosu E, Gardner L, Sportelli P, Anderson KC. Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial. J Clin Oncol 2011; 29:4243-9. [PMID: 21990396 DOI: 10.1200/jco.2010.33.9788] [Citation(s) in RCA: 102] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022] Open
Abstract
PURPOSE Novel agents have improved patient outcome in relapsed or relapsed/refractory multiple myeloma (MM). Preclinical data show that the novel signal transduction modulator, perifosine, enhances the cytotoxicity of dexamethasone and bortezomib. Clinical data suggest that perifosine in combination with dexamethasone has activity in relapsed or relapsed/refractory MM. PATIENTS AND METHODS In a phase I/II study, perifosine in combination with bortezomib with or without dexamethasone was prospectively evaluated in 84 patients with relapsed or relapsed/refractory MM. All were heavily pretreated and bortezomib exposed; 73% were refractory to bortezomib, and 51% were refractory to bortezomib and dexamethasone. The dose selected for the phase II study was perifosine 50 mg/d plus bortezomib 1.3 mg/m(2), with the addition of low-dose dexamethasone at 20 mg if progression occurred on perifosine plus bortezomib alone. RESULTS An overall response rate (ORR; defined as minimal response or better) of 41% was demonstrated with this combination in 73 evaluable patients, including an ORR of 65% in bortezomib-relapsed patients and 32% in bortezomib-refractory patients. Therapy was generally well tolerated; toxicities, including gastrointestinal adverse effects and fatigue, proved manageable. No treatment-related mortality was seen. Median progression-free survival was 6.4 months, with a median overall survival of 25 months (22.5 months in bortezomib-refractory patients). CONCLUSION Perifosine-bortezomib ± dexamethasone demonstrated encouraging activity in heavily pretreated bortezomib-exposed patients with advanced MM. A phase III trial is underway comparing perifosine-bortezomib plus dexamethasone with bortezomib-dexamethasone in patients with relapsed/refractory MM previously treated with bortezomib.
Collapse
Affiliation(s)
- Paul G Richardson
- Dana-Farber Cancer Institute, 44 Binney St, Dana 1B02, Boston, MA 02115, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
|
26
|
Cheung O, Bar M. Viewpoint and Exemplar Generalization in Visual Prediction. J Vis 2011. [DOI: 10.1167/11.11.858] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
27
|
Kveraga K, Boshyan J, Adams R, Bar M, Mote J, Feldman Barrett L. Threat is separable from stimulus negativity in visual scenes. J Vis 2011. [DOI: 10.1167/11.11.1131] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
28
|
Kveraga K, Ghuman A, Kassam K, Aminoff E, Hamalainen M, Chaumon M, Bar M. Early activation of contextual associations during object recognition. J Vis 2010. [DOI: 10.1167/10.7.1192] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
29
|
Bar M. Contextual associations in the brain: past, present and future. J Vis 2010. [DOI: 10.1167/10.7.981] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
30
|
Thomas C, Kveraga K, Bar M. The basis of global and local visual perception revealed by psychophysical 'lesions'. J Vis 2010. [DOI: 10.1167/10.7.972] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
31
|
Aminoff E, Bar M. Frequency of exposure modulates cortical activity in the contextual associations network. J Vis 2010. [DOI: 10.1167/10.7.744] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
32
|
Skoloudik D, Herzig R, Fadrna T, Bar M, Hradilek P, Roubec M, Jelinkova M, Sanak D, Kral M, Chmelova J, Herman M, Langova K, Kanovsky P. Distal enlargement of the optic nerve sheath in the hyperacute stage of intracerebral haemorrhage. Br J Ophthalmol 2010; 95:217-21. [DOI: 10.1136/bjo.2009.172890] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
33
|
Lo SM, Stein P, Mullaly S, Bar M, Jain D, Pastores GM, Mistry PK. Expanding spectrum of the association between Type 1 Gaucher disease and cancers: a series of patients with up to 3 sequential cancers of multiple types--correlation with genotype and phenotype. Am J Hematol 2010; 85:340-5. [PMID: 20425796 DOI: 10.1002/ajh.21684] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Abstract
In Gaucher disease (GD), inherited deficiency of lysosomal glucocerebrosidase due to mutations in GBA1 gene results in accumulation of glucosylceramide in tissue macrophages, systemic macrophage activation, and a complex multisystemic phenotype. We and others have reported an increased risk of multiple myeloma and other malignancies in non-neuronopathic Type 1 GD (GD1). Here, we describe a subset of GD1 patients with multiple malignancies. In our cohort of 403 patients with GD1, nine patients (2.2%) developed two or three different types of cancers either consecutively or simultaneously. Patients were characterized by age at diagnosis of GD1, GBA1 genotype, disease severity, age at cancer diagnosis, enzyme replacement therapy (ERT) status, and splenectomy status. Of the nine patients, six developed two types of malignancies and three had three cancers each. Overall, the hematologic malignancies comprised lymphoma/leukemia (4) and multiple myeloma (4). Nonhematologic malignancies included colon (2), lung (2), thyroid (2), and prostate cancer (1). Of the seven patients who received ERT, the first cancer was diagnosed before initiation of ERT in all but one. Asplenic patients were more likely to have single or multiple cancers compared with patients with intact spleens (P < 0.0072 and P < 0.0203, respectively). Our data strengthen the association of GD1 and cancer and suggest that patients may be at risk of developing multiple malignancies. We found an association between splenectomy and multiple cancers in GD1. It will be of interest to determine whether timely ERT and declining rates of splenectomy will translate into declining rates of multiple and single cancers.
Collapse
Affiliation(s)
- Sarah M Lo
- Department of Pediatrics, Yale School of Medicine, New Haven, Connecticut 06520-8064, USA
| | | | | | | | | | | | | |
Collapse
|
34
|
Kveraga K, Boshyan J, Bar M. Magnocellular contributions to top-down-facilitation of object recognition. J Vis 2010. [DOI: 10.1167/6.6.813] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
35
|
Gronau N, Neta M, Bar M. Visual contextual representations bind semantic and spatial associations. J Vis 2010. [DOI: 10.1167/6.6.618] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
36
|
Zago L, Bar M. THE RISE AND FALL OF VISUAL PRIMING. J Vis 2010. [DOI: 10.1167/3.9.192] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
37
|
Aminoff E, Vaitsou C, Schacter D, Bar M. The cortical network processing contextual, semantic and physical relationships between visual objects. J Vis 2010. [DOI: 10.1167/2.7.698] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
38
|
Bar M, Aminoff E. Contextual processing of visual objects in the brain. J Vis 2010. [DOI: 10.1167/2.7.410] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
39
|
Bar M, Vaitsou C, Schacter D. Gradual activation of visual associations. J Vis 2010. [DOI: 10.1167/1.3.473] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
40
|
Gat-Yablonski G, Lazar L, Bar M, de Vries L, Weintrob N, Phillip M. Growth without growth hormone and similar dysmorphic features in three patients with sporadic combined pituitary hormone deficiencies. Horm Res 2009; 72:302-9. [PMID: 19844116 DOI: 10.1159/000245932] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/24/2008] [Accepted: 01/15/2009] [Indexed: 11/19/2022]
Abstract
BACKGROUND/AIMS Mutations in the HESX1 gene are associated with a broad spectrum of phenotypes: septo-optic dysplasia, midline defects, pituitary abnormalities with consequent hypopituitarism, isolated growth hormone (GH) deficiency or combined pituitary hormone deficiencies (CPHD). This study examined the prevalence of mutations in the HESX1 gene in patients with CPHD. PATIENTS/METHODS Sixty patients with sporadic CPHD without septo-optic dysplasia were screened for mutations in HESX1. RESULTS Three patients were found to be heterozygous for the same Asn125Ser variant in the HESX1 gene. In all 3, panhypopituitarism was presented in the neonatal period, manifested by severe hypoglycemia and neonatal jaundice in 2 patients and respiratory distress in 1. Remarkable findings from physical examination included coarse face; prominent, large, low-set ears; and skeletal abnormalities. Magnetic resonance imaging, performed in 2 patients, revealed a hypoplastic anterior and ectopic posterior pituitary without other midline anomalies. Despite persistent GH deficiency and undetectable levels of insulin-like growth factor 1, all patients had normal linear growth along the 10-25th percentile without GH therapy. CONCLUSION The present study expands the clinical picture of HESX1 mutations by demonstrating that patients heterozygous for Asn125Ser may have a severe endocrinologic and neuroradiologic phenotype and similar dysmorphic features appearing very early in life.
Collapse
Affiliation(s)
- G Gat-Yablonski
- The Jesse Z and Sara Lea Shafer Institute for Endocrinology and Diabetes, National Center for Childhood Diabetes, Schneider Children's Medical Center of Israel, and Felsenstein Medical Research Center, IL-49202 Petach Tikva, Israel
| | | | | | | | | | | |
Collapse
|
41
|
|
42
|
Skoloudik D, Herzig R, Fadrna T, Bar M, Zapletal O, Blatny J, Langova K, Kanovsky P, Kral M. FP19-TU-01 Sono-thrombolytic activation of the fibrinolytic system in acute stroke patients using a diagnostic 1–4MHz transcranial probe. J Neurol Sci 2009. [DOI: 10.1016/s0022-510x(09)70362-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
43
|
Abstract
The parahippocampal cortex (PHC) has been implicated in the processing of place-related information. It has also been implicated in episodic memory, even for items that are not related to unique places. How could the same cortical region mediate such seemingly different cognitive processes? Both processes rely on contextual associations, and we therefore propose that the PHC should be viewed not as exclusively dedicated for analyzing place-related information, or as solely processing episodic memories, but instead as more generally playing a central role in contextual associative processing. To test this proposal, we created a novel learning paradigm to form new associations among meaningless visual patterns. These new associations were created to emulate either spatial or nonspatial contexts. Both spatial and nonspatial associations activated the PHC more than noncontextual items. Moreover, items from spatial contexts activated the posterior part of the PHC, whereas items from nonspatial contexts activated the anterior PHC. Therefore, we show that the PHC plays a role of processing contextual associations in general, and that these associations are not restricted to spatial information. By modifying the existing view of the PHC function accordingly, the seemingly contradicting processes that activate it can be reconciled under one overarching framework.
Collapse
Affiliation(s)
- E Aminoff
- Martinos Center for Biomedical Imaging at MGH, Harvard Medical School, Cahrlestown, MA 02129, USA
| | | | | |
Collapse
|
44
|
Bar M, Kassam KS, Ghuman AS, Boshyan J, Schmid AM, Schmidt AM, Dale AM, Hämäläinen MS, Marinkovic K, Schacter DL, Rosen BR, Halgren E. Top-down facilitation of visual recognition. Proc Natl Acad Sci U S A 2006; 103:449-54. [PMID: 16407167 PMCID: PMC1326160 DOI: 10.1073/pnas.0507062103] [Citation(s) in RCA: 940] [Impact Index Per Article: 52.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2005] [Accepted: 11/23/2005] [Indexed: 11/18/2022] Open
Abstract
Cortical analysis related to visual object recognition is traditionally thought to propagate serially along a bottom-up hierarchy of ventral areas. Recent proposals gradually promote the role of top-down processing in recognition, but how such facilitation is triggered remains a puzzle. We tested a specific model, proposing that low spatial frequencies facilitate visual object recognition by initiating top-down processes projected from orbitofrontal to visual cortex. The present study combined magnetoencephalography, which has superior temporal resolution, functional magnetic resonance imaging, and a behavioral task that yields successful recognition with stimulus repetitions. Object recognition elicited differential activity that developed in the left orbitofrontal cortex 50 ms earlier than it did in recognition-related areas in the temporal cortex. This early orbitofrontal activity was directly modulated by the presence of low spatial frequencies in the image. Taken together, the dynamics we revealed provide strong support for the proposal of how top-down facilitation of object recognition is initiated, and our observations are used to derive predictions for future research.
Collapse
Affiliation(s)
- M Bar
- Martinos Center at Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Gronau N, Neta M, Bar M. Combined and dissociable effects of spatial and semantic contextual information on visual object recognition. J Vis 2005. [DOI: 10.1167/5.8.853] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
46
|
|
47
|
Fenske MJ, Boshyan J, Bar M. Can a gun prime a hairbrush? The "initial guesses" that drive top-down contextual facilitation of object recognition. J Vis 2005. [DOI: 10.1167/5.8.851] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
48
|
Boshyan J, Fenske M, Aminoff E, Bar M. Cortical manifestations of context-related facilitation of visual object recognition. J Vis 2005. [DOI: 10.1167/5.8.852] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
49
|
|
50
|
Ghuman AS, Kassam KS, Boshyan H, Bar M. Cortical interactions in top-down facilitation of visual object recognition through low spatial frequencies. J Vis 2005. [DOI: 10.1167/5.8.89] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|